Irina Chuckowree

The Identification of 2-(1<i>H</i>-Indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-<i>d</i>]pyrimidine (GDC-0941) as a Potent, Selective, Orally Bioavailable Inhibitor of Class I PI3 Kinase for the Treatment of Cancer

Adrian Folkes, Khatereh Ahmadi, W. Alderton et al. · Journal of Medicinal Chemistry · 2008 · 739 citations · Full text

Pi3 Kinase, Chemoprevention Strategy, Pharmacotherapy +18

Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: from PI-103 through PI-540, PI-620 to the oral agent GDC-0941

Florence I. Raynaud, Suzanne A. Eccles, Sonal Patel et al. · Molecular Cancer Therapeutics · 2009 · 270 citations · Full text

Small molecule induced reactivation of mutant p53 in cancer cells

Xiangrui Liu, Rainer Wilcken, Andreas C. Joerger et al. · Nucleic Acids Research · 2013 · 224 citations · Full text

Protein Assembly, Y220c Mutant, Molecular Biology +20

Discovery of a Potent, Selective, and Orally Available Class I Phosphatidylinositol 3-Kinase (PI3K)/Mammalian Target of Rapamycin (mTOR) Kinase Inhibitor (GDC-0980) for the Treatment of Cancer

Daniel P. Sutherlin, Linda Bao, Megan Berry et al. · Journal of Medicinal Chemistry · 2011 · 212 citations · Full text

Translational Pharmacology, Pre-clinical Pharmacology, Molecular Pharmacology +20

Novel Angular Benzophenazines:  Dual Topoisomerase I and Topoisomerase II Inhibitors as Potential Anticancer Agents

Nigel Vicker, Luke Burgess, Irina Chuckowree et al. · Journal of Medicinal Chemistry · 2002 · 131 citations

Medicinal Chemistry, Pharmaceutical Chemistry, Bioorganic Chemistry +15